{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:49:15Z","timestamp":1785836955936,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hrain Biotechnology Co.,\u00a0Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chimeric antigen receptor T (CAR-T) cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells. Despite several CAR-T products being approved and commercialized in the USA, Europe, and China, CAR-T products still require additional optimization to ensure reproducible and cost-effective manufacture. Here, we investigated the critical parameters in the CD3<jats:sup>+<\/jats:sup>T-cell isolation process that significantly impacted CAR-T manufacturing's success.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>CAR-T cells were prepared from cryopreserved peripheral blood mononuclear cells (PBMC). The thawed PBMC was rested overnight before the CD3<jats:sup>+<\/jats:sup>T cell isolation process using CTS<jats:sup>\u2122<\/jats:sup>Dynabeads<jats:sup>\u2122<\/jats:sup>CD3\/CD28. Different isolation media, cell-bead co-incubation time, and cell density were examined in this study. Activated CD3<jats:sup>+<\/jats:sup>T cells were transduced with a gamma retroviral vector carrying the CD19 or BCMA CAR sequence. The CAR-T cells proliferated in a culture medium supplemented with interleukin 2 (IL-2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CD14<jats:sup>+<\/jats:sup>monocytes hindered T-cell isolation when X-VIVO 15 basic medium was used as the selection buffer. The activation of T cells was blocked because monocytes actively engulfed CD3\/28 beads. In contrast, when DPBS was the selection medium, the T-cell isolation and activation were no longer blocked, even in patients whose PBMC contained abnormally high CD14<jats:sup>+<\/jats:sup>monocytes and a low level of CD3<jats:sup>+<\/jats:sup>T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, we discovered that selecting CD3<jats:sup>+<\/jats:sup>T-cell isolation media is critical for improving T-cell activation, transduction, and CAR-T proliferation. Using DPBS as a CD3<jats:sup>+<\/jats:sup>T cell isolation buffer significantly improved the success rate and shortened the duration of CAR-T production. The optimized process has been successfully applied in our ongoing clinical trials.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>NCT03798509: Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia. Date of registration: January 10, 2019. NCT03720457: Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. Date of registration: October 25, 2018. NCT04003168: Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed\/Refractory Multiple Myeloma. Date of registration: July 1, 2019<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-022-03833-6","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T22:21:07Z","timestamp":1671488467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct03798509","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03720457","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04003168","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Haiying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ting","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-3470","authenticated-orcid":false,"given":"Hong-Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"3833_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"3833_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term Follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"3833_CR3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"3833_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"3833_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","volume":"21","author":"C Roddie","year":"2019","unstructured":"Roddie C, O\u2019Reilly M, Pinto JDA, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21:327\u201340.","journal-title":"Cytotherapy"},{"key":"3833_CR6","unstructured":"Considerations for the development of chimeric antigen receptor (CAR) T cell products draft guidance for industry. U.S. Food and Drug Administration; 2022. p. 36."},{"key":"3833_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3833_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.beha.2018.01.002","volume":"31","author":"AP Gee","year":"2018","unstructured":"Gee AP. GMP CAR-T cell production. Best Pract Res Clin Haematol. 2018;31:126\u201334.","journal-title":"Best Pract Res Clin Haematol"},{"key":"3833_CR9","doi-asserted-by":"publisher","first-page":"720692","DOI":"10.3389\/fphar.2021.720692","volume":"12","author":"A Hernandez-Lopez","year":"2021","unstructured":"Hernandez-Lopez A, Tellez-Gonzalez MA, Mondragon-Teran P, Meneses-Acosta A. Chimeric antigen receptor-T cells: a pharmaceutical scope. Front Pharmacol. 2021;12:720692.","journal-title":"Front Pharmacol"},{"key":"3833_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2:408\u201322.","journal-title":"Blood Cancer Discov"},{"key":"3833_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"3833_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"3833_CR13","unstructured":"User Guide: CTSTM DynabeadsTM CD3\/CD28 (Catalog No. 40203D). Thermo Fisher Scientific; 2021."},{"key":"3833_CR14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cyto.a.20859","volume":"77","author":"P Autissier","year":"2010","unstructured":"Autissier P, Soulas C, Burdo TH, Williams KC. Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans. Cytometry A. 2010;77:410\u20139.","journal-title":"Cytometry A"},{"key":"3833_CR15","doi-asserted-by":"publisher","first-page":"119627","DOI":"10.1016\/j.lfs.2021.119627","volume":"277","author":"K Mortezaee","year":"2021","unstructured":"Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci. 2021;277:119627.","journal-title":"Life Sci"},{"key":"3833_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","volume":"22","author":"P Braendstrup","year":"2020","unstructured":"Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22:57\u201369.","journal-title":"Cytotherapy"},{"key":"3833_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/healthcare9081062","volume":"9","author":"NA Ivica","year":"2021","unstructured":"Ivica NA, Young CM. Tracking the CAR-T revolution: analysis of clinical trials of CAR-T and TCR-T therapies for the treatment of cancer (1997\u20132020). Healthcare. 2021;9:1062.","journal-title":"Healthcare"},{"key":"3833_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","volume":"27","author":"M Alexander","year":"2021","unstructured":"Alexander M, Culos K, Roddy J, Shaw JR, Bachmeier C, Shigle TL, Mahmoudjafari Z. Chimeric antigen receptor t cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration. Transplant Cell Ther. 2021;27:558\u201370.","journal-title":"Transplant Cell Ther"},{"key":"3833_CR19","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.","journal-title":"Mol Ther Oncolytics"},{"key":"3833_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcyt.2016.05.009","volume":"18","author":"U Mock","year":"2016","unstructured":"Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy. 2016;18:1002\u201311.","journal-title":"Cytotherapy"},{"key":"3833_CR21","doi-asserted-by":"publisher","first-page":"17832","DOI":"10.1038\/s41598-020-74595-8","volume":"10","author":"MP Poltorak","year":"2020","unstructured":"Poltorak MP, Graef P, Tschulik C, Wagner M, Cletiu V, Dreher S, Borjan B, Fraessle SP, Effenberger M, Turk M, et al. Expamers: a new technology to control T cell activation. Sci Rep. 2020;10:17832.","journal-title":"Sci Rep"},{"key":"3833_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/jlb.61.5.583","volume":"61","author":"K Ino","year":"1997","unstructured":"Ino K, Singh RK, Talmadge JE. Monocytes from mobilized stem cells inhibit T cell function. J Leukoc Biol. 1997;61:583\u201391.","journal-title":"J Leukoc Biol"},{"key":"3833_CR23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1567-5769(01)00062-5","volume":"1","author":"K Ino","year":"2001","unstructured":"Ino K, Ageitos AG, Singh RK, Talmadge JE. Activation-induced T cell apoptosis by monocytes from stem cell products. Int Immunopharmacol. 2001;1:1307\u201319.","journal-title":"Int Immunopharmacol"},{"key":"3833_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","volume":"18","author":"DF Stroncek","year":"2016","unstructured":"Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, Khuu H, Merchant MS, Mackall CL. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy. 2016;18:893\u2013901.","journal-title":"Cytotherapy"},{"key":"3833_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbmt.2018.10.004","volume":"25","author":"A Kunkele","year":"2019","unstructured":"Kunkele A, Brown C, Beebe A, Mgebroff S, Johnson AJ, Taraseviciute A, Rolczynski LS, Chang CA, Finney OC, Park JR, Jensen MC. Manufacture of chimeric antigen receptor t cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion. Biol Blood Marrow Transplant. 2019;25:223\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3833_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","volume":"22","author":"X Wang","year":"2021","unstructured":"Wang X, Borquez-Ojeda O, Stefanski J, Du F, Qu J, Chaudhari J, Thummar K, Zhu M, Shen LB, Hall M, et al. Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. Mol Ther Methods Clin Dev. 2021;22:377\u201387.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3833_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","volume":"20","author":"E Noaks","year":"2021","unstructured":"Noaks E, Peticone C, Kotsopoulou E, Bracewell DG. Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing. Mol Ther Methods Clin Dev. 2021;20:675\u201387.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3833_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12967-017-1160-5","volume":"15","author":"DF Stroncek","year":"2017","unstructured":"Stroncek DF, Lee DW, Ren J, Sabatino M, Highfill S, Khuu H, Shah NN, Kaplan RN, Fry TJ, Mackall CL. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. J Transl Med. 2017;15:59.","journal-title":"J Transl Med"},{"key":"3833_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1600-0765.1969.tb01980.x","volume":"4","author":"A Attramadal","year":"1969","unstructured":"Attramadal A. The effect of divalent cations on cell adhesion. J Periodontal Res. 1969;4:281\u20135.","journal-title":"J Periodontal Res"},{"key":"3833_CR30","first-page":"226","volume":"47","author":"R Damluji","year":"1979","unstructured":"Damluji R, Riley PA. On the role of calcium in adhesion of cells to solid substrates. Exp Cell Biol. 1979;47:226\u201337.","journal-title":"Exp Cell Biol"},{"key":"3833_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0014-4827(72)90480-6","volume":"74","author":"M Takeichi","year":"1972","unstructured":"Takeichi M, Okada TS. Roles of magnesium and calcium ions in cell-to-substrate adhesion. Exp Cell Res. 1972;74:51\u201360.","journal-title":"Exp Cell Res"},{"key":"3833_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1247\/csf.1.377","volume":"1","author":"MJ Ueda","year":"1976","unstructured":"Ueda MJ, Takeichi M. Two mechanisms in cell adhesion revealed by effects of divalent cations. Cell Struct Funct. 1976;1:377\u201388.","journal-title":"Cell Struct Funct"},{"key":"3833_CR33","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1007\/s12035-019-1519-0","volume":"56","author":"TR Carden","year":"2019","unstructured":"Carden TR, Correale J, Pasquini JM, Perez MJ. Transferrin enhances microglial phagocytic capacity. Mol Neurobiol. 2019;56:6324\u201340.","journal-title":"Mol Neurobiol"},{"key":"3833_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1006\/bbrc.1996.5935","volume":"230","author":"H Sakamoto","year":"1997","unstructured":"Sakamoto H, Sakamoto N, Oryu M, Kobayashi T, Ogawa Y, Ueno M, Shinnou M. A novel function of transferrin as a constituent of macromolecular activators of phagocytosis from platelets and their precursors. Biochem Biophys Res Commun. 1997;230:270\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"3833_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12967-018-1384-z","volume":"16","author":"J Jin","year":"2018","unstructured":"Jin J, Gkitsas N, Fellowes VS, Ren J, Feldman SA, Hinrichs CS, Stroncek DF, Highfill SL. Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules. J Transl Med. 2018;16:13.","journal-title":"J Transl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03833-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03833-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T08:13:44Z","timestamp":1701591224000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03833-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3833"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03833-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research involving human material has been performed by the Declaration of Helsinki. All patients provided written informed consent before the beginning of the clinical trials mentioned in this study. The ethical committee approved the study of Hrain Biotechnology Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H-MH was hired full-time by Hrain Biotechnology Co., Ltd. HW, S-TT, MG, CF, XL, MZ, NL, and FH are employed full-time by Hrain Biotechnology Co., Ltd. H-MH, HW, S-TT and MG have pending patents on CAR products developed at Hrain Biotechnology Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"608"}}